3 results
Primary: To assess the efficacy of treatment with 300 mg or 600 mg of intravenous (IV) zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily on time to clinical response. Secondary: reduction in viral load from nasopharyngeal swabs…
PrimaryThe primary objective of this study is to assess the safety and tolerability of BEN2293, administered as multiple topical doses to increasing body surface area (BSA), in patients with mild to moderate AD.SecondaryPharmacokinetics· To…
Primary* To evaluate safety and tolerability of LNP3794 at selected dose levelsSecondary* To determine the therapeutic relevant dose(s) of LNP3794* To describe the PK profile of LNP3794 following single and multiple oral administrationOther* To…